Skepticism and Hope Surround Ozempic and Wegovy Amid Obesity Crisis

While many Americans doubt the effectiveness of new weight loss drugs, Goldman Sachs predicts a significant economic boost if widely adopted.

A majority of Americans are skeptical about the effectiveness of weight loss drugs like Ozempic and Wegovy in significantly reducing the country's obesity rate.
Goldman Sachs estimates that widespread adoption of GLP-1 agonists could add up to 1% to America's GDP, with a potential user base of 10 to 70 million by 2028.
The FDA has approved Ozempic for managing Type 2 diabetes and Wegovy for long-term weight management, highlighting their medical credibility.
Concerns over rising drug prices and counterfeit versions may deter potential users, despite the drugs' popularity.
The debate over the role of genetics versus willpower in weight loss success continues, with 65% of Americans believing willpower alone is not enough for sustainable weight loss.